The risks of the use of nuclear, radiological, biological or chemical (NRBC) weapons are heterogeneous. Each risk has its own implications for developing and deploying any capacity to assist victims of an NRBC event and, in parallel, for the health and security of the people bringing this assistance.... At an international level, there are no plans for assisting the victims of an NRBC event which are both adequate and safe. Recognizing
the realities of the contexts associated with each risk throws up numerous challenges; such recognition is also a prerequisite for addressing these challenges. The realities that have to be considered relate to:
1. developing, acquiring, training for and planning an NRBC response capacity;
2. deploying a response capacity in an NRBC event;
3. the mandates and policies of international organizations pertaining to NRBC events. The challenges that will pose the greatest difficulty for a humanitarian organization are those for which the solutions are ‘non-buyable’ and which involve making extremely difficult decisions. Attempting to assist victims of an NRBC event without a reality-based approach might generate ineffective and unacceptably dangerous situations for those involved.
more
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of ivermectin to treat patients with COVID-19 needing mechanical venti...lation. However, neither of these studies were peer-reviewed nor formally published and one of them was later retracted.
more
TheoreticalMedicine 6 (1985), 281-294. 0167-9902/85.10
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets.
more
Technical Report
AIDS Medicines and diagnostics service
July 2015
The OIE has been working on the AMR issue for a long
time. In undertaking its role as a standard- setting organisation*
for animal health, including zoonoses, the OIE has developed
a wide range of international standards on antimicrobial
agents, in particular on responsible and prudent use.
The...se standards are regularly reviewed and updated
through the transparent and inclusive process of expert
advice and member consultation before presentation for
adoption to the World Assembly of Delegates from our
180 Member Countries each year. The OIE also works with
its Member countries in a comprehensive and continuous
capacity building process for their Veterinary Services.
more
DHS Working Papers No. 114
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office
of AIDS Research Advisory Council (OARAC)
6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.